about
Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosisBone disease in newly diagnosed lupus nephritis patientsOsteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.Cellular and molecular mechanisms underlie the anti-tumor activities exerted by Walterinnesia aegyptia venom combined with silica nanoparticles against multiple myeloma cancer cell types.Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma.Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis.Review of osteoimmunology and the host response in endodontic and periodontal lesions.Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.Role of chemokines in tumor growth.Bone marrow microenvironment and the identification of new targets for myeloma therapy.Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cellsPlasma Levels of Monocyte Chemotactic Protein-1 Are Associated with Clinical Features and Angiogenesis in Patients with Multiple Myeloma.Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple MyelomaExtramedullary myeloma in an HIV-seropositive subject. Literature review and report of an unusual case.Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.Myeloma bone disease: pathogenesis, current treatments and future targets.Psoriatic cutaneous inflammation promotes human monocyte differentiation into active osteoclasts, facilitating bone damage.Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.Association of promyelocytic leukemia protein with expression of IL-6 and resistance to treatment in multiple myeloma.Role of interleukin 16 in multiple myeloma.Involvement of the TGFβ1/Smad2/MMP3 signaling pathway in SB431542-induced inhibition of cell invasion in multiple myeloma RPMI 8226 cells.TNF α mediated IL-6 secretion is regulated by JAK/STAT pathway but not by MEK phosphorylation and AKT phosphorylation in U266 multiple myeloma cells.Cell Trafficking in Multiple MyelomaTranscriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments.Multiple myeloma: biology, standard therapy, and transplant therapy.The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple.Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins.Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.CCL2 and CCR2 are Essential for the Formation of Osteoclasts and Foreign Body Giant Cells.Impaired efferocytosis by monocytes in multiple myeloma.
P2860
Q28476755-D7331AF8-484B-4068-8B64-101FF2BAC742Q28543032-CB95872D-BDCF-4AA0-929D-7F350CF2F2BFQ33564854-BFE74078-7C3E-4261-A8C2-BAFF953709B7Q33930081-F2616675-3FB1-4D7A-805C-E67E3079B0E0Q34517100-F5092363-796C-4A2C-8D08-DEA0A4D99DE5Q34540657-817F875F-ED12-47DE-892C-6F2BC4A0F8A5Q34613489-F0A6D0EF-D6E2-41A7-9DD3-7E76D45C93BFQ34920792-CA2A5ADC-60EF-4926-9841-99B14B606B14Q34956540-5AC34D41-D473-46FB-975C-C2E464627309Q35067806-DDB8AF7A-7D40-4160-A860-68074DF0CB5DQ35483867-84BDF3DB-B162-4E66-AE7D-E00590E793DAQ35539175-7A40CBD3-1B9E-4B83-B35F-D5CE2018FB4FQ36120825-94281211-1923-4645-89B6-14D4B36CB6CBQ36162703-2814E6CC-1DDE-4B67-BDF3-B23E72BE7274Q36384761-449686F2-676E-4222-9E95-1F39CE14BB4FQ36564495-A90486EB-D31A-469C-B36B-37CBE518A8D7Q36642956-D7FF74F3-06A2-4715-A90F-F7ACCEA439BCQ37114131-CCE39D13-727F-4CF8-B18E-D694E2EC7F26Q37351173-B414DE8D-6873-4650-BCC1-1B1BE4DA1550Q37652169-078BF51A-3BFA-410E-AC8B-B7342B24E5D7Q38035044-42AB384A-F39D-4677-BCF9-3AC7E038D353Q38073136-201DC587-CEF1-4594-AEAF-F608AD8DF7AEQ38155039-D472D302-41D1-461F-BEF2-17B2B70F0425Q38246241-481EDBED-E7B2-4643-83A4-EC88054B1B32Q38848576-7BD46EEA-D064-452A-ACBF-3266787245A6Q39203918-9FB4F087-E583-4B37-B364-1610F4987CE0Q39294366-697B38A5-ED71-4B1F-ACF8-319DCE725C9DQ39322974-E9EBA19D-A861-4D84-A3DE-D4590717DD10Q40979196-B2130FA8-83B4-4984-8F0A-611DB7119A2FQ41760888-2E4970BE-6D7C-44CB-9724-A002CE053983Q42146660-117F3915-F30A-442E-8E2D-34BE22D230B4Q42158465-E53C36F2-FCCD-4687-915F-C107031F7716Q42244787-3D7F8240-18BC-438F-BEEF-1D53C5AE7D93Q42794048-A7A176F7-3C62-42C9-BCF7-5A3D64076627Q46554858-C0958013-E492-4BF3-BFA7-17452CB25342Q47132349-04F4E94F-87F6-480B-A2F6-4BD9848651A6Q47909734-D4BD206E-8444-438E-8FEF-A441643D3DCFQ53090715-2275699A-1016-4C35-BC19-D87CDA23B00EQ55310900-8BDECE4D-D623-4588-A335-3118C620F981
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Chemokines in multiple myeloma
@ast
Chemokines in multiple myeloma
@en
type
label
Chemokines in multiple myeloma
@ast
Chemokines in multiple myeloma
@en
prefLabel
Chemokines in multiple myeloma
@ast
Chemokines in multiple myeloma
@en
P2093
P2860
P1476
Chemokines in multiple myeloma
@en
P2093
G David Roodman
Irene M Ghobrial
Rohit Aggarwal
P2860
P304
P356
10.1016/J.EXPHEM.2006.06.017
P577
2006-10-01T00:00:00Z